✨KEYNOTE-407✨
♦️Phase III
♦️Untreated metastatic, squamous NSCLC
♦️Pts randomized 1:1 pembro+platinum-doublet vs plat doublet alone
♦️Median OS 15.9 mos vs 11.3 mos
♦️69.8% of grade 3+ AEs in pembro-combo vs 68.2% in placebo-combo
Sep 7, 2022 • 19 tweets • 108 min read
@TumorBoardTues 1/17 #TumorBoardTuesday#LungCancer#OncTwitter
72y 👩🏻with 58 pk-yr 🚬hx
Chest pain
PMH: diabetes
CT: 3 cm LLL nodule & left pleural effusion with 5mm nodule in LUL
PET: GGO in LLL SUV 4.5
💉thora with cytology
🔬Stage IVA (T4N0M1a) 🫁 adenoCa
38yo 👩🏻with remote 8 pk-yr 🚬hx
CP & diarrhea
PMH: None
🩻: 2 cm focal consolidations in the LLL
PET: GGO in LLL SUV 4.5
🔪+ mediastinal staging
🔬pT2a, pN1 (Stage IIB) lung adenoCa
🤨What adjuvant systemic tx would YOU give next?
@TumorBoardTues 2/16 #TumorBoardTuesday#LCSM#LungCancer
🧪 Resected 🫁 tissue tested
🦠 Tissue NGS and IHC was sent 🧬
🔬 NGS: EGFR exon 19 deleted
🔬 PD-L1 52%
🤨 What adjuvant treatment plan do you initiate next?
Feb 10, 2021 • 5 tweets • 3 min read
Many times in the past, I have not recognized the disparities that lie within our community. Part of it comes from the narrative of the monolith and my own privilege within this narrative 🙇🏽♀️
As I learn, I want to share these excellent infographics by @fit_pham (on @instagram)
19 origin groups
\ /
\ /
\ /
\ /
ASIANS
